98%
921
2 minutes
20
Unlabelled: is difficult to treat owing to its intrinsic and acquired resistance to antibiotics, particularly vancomycin. Vancomycin-resistant is an important cause of bloodstream infections in healthcare settings with limited treatment options. This study aimed to analyze the risk factors for vancomycin-resistant bloodstream infection. This retrospective analysis of data from the Munich Multicentric Enterococci Cohort analyzed 200 episodes of nonrecurrent vancomycin-susceptible bloodstream infection and 196 episodes of nonrecurrent vancomycin-resistant bloodstream infection from six hospitals in Munich, Germany, between 2010 and 2019. Logistic regression was used to identify risk factors for vancomycin-resistant bloodstream infection. In the unadjusted analysis, the risk factors for vancomycin-resistant bloodstream infection included the length of hospital stay, previous treatment with vancomycin or linezolid, and solid organ transplantation. In the multivariable analysis, prior treatment with vancomycin and solid organ transplantation were independent risk factors for vancomycin-resistant bloodstream infection. Vancomycin resistance was not significantly associated with the severity of underlying diseases. This study identified prior vancomycin treatment and solid organ transplantation as key independent risk factors for vancomycin-resistant bloodstream infection.
Importance: Vancomycin-resistant is a growing threat in healthcare settings, challenging the management of enterococcal infections. This study identified prior treatment with vancomycin and solid organ transplantation as risk factors for vancomycin-resistant bloodstream infections. Based on the analysis of five disease severity scores for acute and chronic illness, the severity of underlying diseases could not be demonstrated to be a risk factor for the occurrence of vancomycin resistance in bloodstream infections.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210936 | PMC |
http://dx.doi.org/10.1128/spectrum.00052-25 | DOI Listing |
J Microbiol Immunol Infect
September 2025
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Objectives: Vancomycin-resistant enterococcal bloodstream infections (VRE-BSIs) carry high mortality in patients with malignancy. While neutropenia is a known risk factor for mortality in patients with malignancy and BSI, its impact on the effectiveness of daptomycin and linezolid in VRE-BSI is not well defined.
Methods: We conducted a multicenter cohort study of hospitalized patients aged ≥18 years with malignancy and VRE-BSI between 2010 and 2021.
Cell Metab
August 2025
Section of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. Electronic address:
Diet and obesity contribute to insulin resistance and type 2 diabetes, in part via the gut microbiome. To explore the role of gut-derived metabolites in this process, we assessed portal/peripheral blood metabolites in mice with different risks of obesity/diabetes, challenged with a high-fat diet (HFD) + antibiotics. In diabetes/obesity-prone C57BL/6J mice, 111 metabolites were portally enriched and 74 were peripherally enriched, many of which differed in metabolic-syndrome-resistant 129S1/129S6 mice.
View Article and Find Full Text PDFCurr Opin Crit Care
October 2025
ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Purpose Of Review: This review aims to summarize current recommendations for the management of serious infections, such as bloodstream infections (BSIs) and ventilator-associated pneumonia, caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, focusing on evidence from randomized controlled trials (RCTs) and emerging treatment options.
Recent Findings: Vancomycin, linezolid, and daptomycin represent the main therapeutic options for the management of methicillin-resistant Staphylococcus aureus infections; among newer agents, ceftobiprole has recently gained approval for BSI treatment. For vancomycin-resistant Enterococcus faecium BSIs, linezolid and daptomycin remain commonly employed despite the lack of comparative RCTs guiding treatment decisions.
Microbiol Spectr
September 2025
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Mixed bloodstream infections (BSIs) involving and other bacterial pathogens present significant diagnostic and therapeutic challenges. The incidence of these co-infections has been increasing. However, the limited literature on this topic necessitates a deeper understanding of its epidemiological and clinical characteristics.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
Monash Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia.
The clinical landscape of Gram-positive infections has been reshaped with the introduction of long-acting lipoglycopeptides, particularly dalbavancin and oritavancin. Both agents share broad-spectrum activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains, yet differ markedly in pharmacokinetics, pharmacodynamics, resistance profiles, and clinical adoption. This review presents a comprehensive comparative analysis of their structural innovations, distinct pharmacokinetic and pharmacodynamic characteristics, and dual mechanisms of action, supported by minimum inhibitory concentration data across key pathogens.
View Article and Find Full Text PDF